Woodstock Corp boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 92,201 shares of the company’s stock after buying an additional 375 shares during the period. Johnson & Johnson makes up approximately 2.2% of Woodstock Corp’s investment portfolio, making the stock its 7th largest position. Woodstock Corp’s holdings in Johnson & Johnson were worth $16,287,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. TD Capital Management LLC acquired a new position in Johnson & Johnson during the third quarter valued at $48,000. Cowa LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $58,000. Legend Financial Advisors Inc. purchased a new position in Johnson & Johnson in the third quarter valued at about $59,000. Adirondack Retirement Specialists Inc. purchased a new position in Johnson & Johnson in the third quarter valued at about $67,000. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $84,000. 67.94% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
JNJ has been the topic of a number of recent research reports. Atlantic Securities boosted their target price on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. SVB Leerink decreased their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday. They set a “strong-buy” rating for the company. Finally, Piper Sandler decreased their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.73.
Johnson & Johnson Trading Down 1.1 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the prior year, the firm posted $2.13 EPS. Johnson & Johnson’s quarterly revenue was down 4.4% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is 67.06%.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.35% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.